These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20360719)

  • 21. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
    Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL
    Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
    Press RD
    Mol Diagn; 2001 Sep; 6(3):211-3. PubMed ID: 11571715
    [No Abstract]   [Full Text] [Related]  

  • 25. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 27. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
    van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
    Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hope for leukemia.
    Lichtman MA
    Health News; 2001 Jan; 7(1):3. PubMed ID: 11198409
    [No Abstract]   [Full Text] [Related]  

  • 29. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 31. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
    Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
    Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicine. (De)personalized medicine.
    Horwitz RI; Cullen MR; Abell J; Christian JB
    Science; 2013 Mar; 339(6124):1155-6. PubMed ID: 23471391
    [No Abstract]   [Full Text] [Related]  

  • 33. Nilotinib versus imatinib: molecular mechanism(s) of its better efficacy.
    Bakalova R; Zhelev Z; Spasov L
    Cancer; 2012 Oct; 118(20):5180-1; author reply 5181-2. PubMed ID: 22535585
    [No Abstract]   [Full Text] [Related]  

  • 34. Ariad Pharmaceutical's ninja cancer drug inhibits armies of mutants.
    Wolfson W
    Chem Biol; 2012 Sep; 19(9):1075-6. PubMed ID: 22999871
    [No Abstract]   [Full Text] [Related]  

  • 35. The era of cancer discovery.
    Cantley LC; Baselga J
    Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
    [No Abstract]   [Full Text] [Related]  

  • 36. From genomic landscapes to personalized cancer management-is there a roadmap?
    Swanton C; Caldas C
    Ann N Y Acad Sci; 2010 Oct; 1210():34-44. PubMed ID: 20973797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of genomics on personalized cancer medicine.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial: New Experimental and Computational Tools for Drug Discovery: From Chemistry to Biology. Part-II.
    Sylla-Iyarreta Veitia M; Dumas F; Gonzalez-Diaz H
    Curr Top Med Chem; 2017; 17(26):2901-2902. PubMed ID: 29041874
    [No Abstract]   [Full Text] [Related]  

  • 39. [Programs for continuing medical education: B session 7. Progress in treatment for hematologic diseases].
    Higashihara M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):717-23. PubMed ID: 24796142
    [No Abstract]   [Full Text] [Related]  

  • 40. A fast track to personalized medicine?: whole-genome sequencing may lead to better cancer therapies.
    Nelson B
    Cancer Cytopathol; 2012 Oct; 120(5):283-4. PubMed ID: 23065928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.